Lyon (France), November 13, 2024, at 5:45 p.m. CET - PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, ...
S4V2 will be tested for safety and preliminary efficacy in approximately 120 healthy Shigella -naïve participants aged 18 to 50 years at three sites in the United States. The study, sponsored and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback